GlassScriptPhysician profile
Rise C Hatten
NPI 1265499271
$1,161.87
in general payments reported to CMS, 2019-2025
20 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.31 · 2020: $76.39 · 2021: $301 · 2022: $63.28 · 2023: $159 · 2024: $304 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $199.88 | 2024-2025 | Brixadi |
| Mayne Pharma Commercial LLC | $190.59 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.26 | 2019-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.59 | 2023-2024 | Caplyta |
| Dexcom, INC. | $69.54 | 2023-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $64.83 | 2019-2025 | |
| Hologic Sales and Service, LLC | $64.29 | 2023-2025 | Aptima, Coolseal Generator, Novasure |
| Janssen Pharmaceuticals, INC | $64.27 | 2020-2024 | Invega Sustenna |
| Agile Therapeutics, INC. | $60.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $50.24 | 2021-2022 | |
| Novo Nordisk INC | $49.70 | 2019-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $37.55 | 2021-2022 | |
| Amgen INC. | $30.42 | 2020-2024 | Evenity |
| Otsuka America Pharmaceutical, INC. | $26.84 | 2023 | Rexulti |
| Insulet Corporation | $22.17 | 2023 | Omnipod |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $17.44 | 2025 | Sublocade |
| Mylan Specialty L.P. | $17.27 | 2023 | Yupelri |
| Viatris Specialty LLC | $17.27 | 2025 | Yupelri |
| Alvogen INC | $16.76 | 2024 | Teriparatide |
| Gilead Sciences, INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rise Hatten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.